Lansforsakringar Fondforvaltning Ab (Publ) Neurocrine Biosciences Inc Transaction History
Lansforsakringar Fondforvaltning Ab (Publ)
- $15.9 Billion
- Q1 2025
A detailed history of Lansforsakringar Fondforvaltning Ab (Publ) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Lansforsakringar Fondforvaltning Ab (Publ) holds 32,446 shares of NBIX stock, worth $4.11 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
32,446
Previous 32,446
-0.0%
Holding current value
$4.11 Million
Previous $4.43 Million
18.97%
% of portfolio
0.02%
Previous 0.03%
Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
649Shares Held
97.1MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.8 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.26 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$700 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$615 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$338 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12.1B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...